GlassScriptPhysician profile
Peyton Wohlwender
NPI 1417533530
$1,154.15
in general payments reported to CMS, 2019-2025
15 companies · $114 in 2025
The $114 reported for 2025 was more than what a typical Pediatrics (Nurse Practitioner) provider received nationally (typical 2025 total: $93.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $275 · 2022: $366 · 2023: $311 · 2024: $88.58 · 2025: $114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $513.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $513.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $464.78 | 2021-2024 | Azstarys |
| Glaxosmithkline, LLC. | $138.93 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $119.78 | 2024-2025 | Qelbree |
| Merck Sharp & Dohme LLC | $116.80 | 2021-2023 | Vaxneuvance, Gardasil 9, M-M-R II |
| Ironshore Pharmaceuticals INC. | $108.17 | 2022-2023 | Jornay Pm |
| Sanofi Pasteur INC. | $36.52 | 2021-2022 | |
| Pfizer INC. | $32.40 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.58 | 2021 | |
| Xeris Pharmaceuticals, INC. | $20.73 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.82 | 2025 | Caplyta |
| Seqirus USA INC | $16.37 | 2021 | |
| Neos Therapeutics, LP | $15.99 | 2024 | Adzenys Xr-Odt |
| Photonicare INC | $15.16 | 2022 | |
| Tris Pharma INC | $14.57 | 2025 | Dyanavel Xr |
| Biomarin Pharmaceutical INC. | $11.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peyton Wohlwender listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.